Diagnostic Value of a Group of MicroRNA Genes Hypermethylated in Ovarian Carcinoma


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

The study was designed to determine genes of microRNAs hypermethylated in malignant ovarian tumors and to select new diagnostic and prognostic markers of the disease and effective system of markers. Using methyl-specific PCR and a representative sample of 54 ovarian cancer specimens, we determined 5 microRNA genes (MIR-34b/c, MIR-9-1, MIR-124-3, MIR-129-2, and MIR-107) hypermethylated in the majority of tumor samples in comparison with paired samples of histologically unchanged tissue (48-57% vs. 4-19%, p<0.001). Using ROC-analysis, we selected an effective system of 4 markers for diagnosis of ovarian cancer (MIR-9-1, MIR-124-3, MIR-129-2, and MIR-107) characterized by high sensitivity and specificity (up to 87-94% at AUC=0.92) relative to the conventional norm (54 paired samples of histologically unchanged tissue) and absolute norm (18 ovarian tissue samples from subjects who died from non-tumor diseases). It was also shown that methylation of MIR-129-2, MIR-9-1, and MIR-34b/c genes is significantly (p<0.01) correlated with the clinical stage or the presence of metastases. The results indicate that epigenetic modifications of the studied microRNA genes are involved in the pathogenesis and progression of ovarian cancer and attest to their diagnostic and prognostic potential.

作者简介

E. Braga

Research Institute of General Pathology and Pathophysiology; Research Center of medical Genetics

编辑信件的主要联系方式.
Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow; Moscow

V. Loginov

Research Institute of General Pathology and Pathophysiology; Research Center of medical Genetics

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow; Moscow

E. Filippova

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

A. Burdennyi

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

I. Pronina

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

T. Kazubskaya

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russian Federation

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

D. Khodyrev

Federal Scientific and Clinical Center of Specialized Medical Assistance and Medical Technologies, Federal Medical and Biological Agency of the Russian Federation

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

D. Utkin

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russian Federation

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

D. Kushlinskii

V. I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russian Federation

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

L. Adamyan

V. I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russian Federation

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

N. Kuslinskii

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russian Federation

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

补充文件

附件文件
动作
1. JATS XML

版权所有 © Springer Science+Business Media, LLC, part of Springer Nature, 2018